PD-L1 scoring was complicated in the various studies performed by the presence of different testing systems based on individual PD-L1 antibody clones (e.g., 22C3, SP142, 28-8, SP263, etc.), testing platforms (e.g., Ventana/Roche, Roche, Basel, Switzerland), DAKO/Agilent, Agilent, Santa Clara, CA, USA), immunotherapeutic agent chosen (pembrolizumab, nivolumab, durvalumab, atezolizumab, etc.), and validity for specific tumor entities, finally leading to different cutoff values to conduct therapy decisions [16,17]. Here, CD274 is linked to neoplasm.